Therapy of Pseudoxanthoma Elasticum: Current Knowledge and Future Perspectives

Area of Science:

• Genetics and rare diseases
• Metabolic disorders
• Dermatology and ophthalmology

Background:

• Pseudoxanthoma elasticum (PXE) is a rare genetic disorder affecting connective tissues, characterized by skin lesions, vision loss, and arterial calcification.
• Pathogenic variants in the ABCC6 gene lead to ABCC6 protein deficiency, causing reduced pyrophosphate levels and dysregulated blood lipids, contributing to PXE pathology.
• PXE significantly impacts patients' quality of life, with current treatment options often being outdated or not widely accessible.

Purpose of the Study:

• To provide a comprehensive overview of current and emerging treatment strategies for Pseudoxanthoma elasticum (PXE).
• To address the challenges faced by clinicians in managing PXE due to evolving therapeutic landscapes.
• To highlight future research and development directions for PXE treatment.

Main Methods:

• Review of currently available clinical treatment options for PXE.
• Analysis of the latest research and development in PXE therapeutics.
• Discussion of future perspectives and potential novel treatment approaches.

Main Results:

• PXE treatment landscape includes outdated therapies and novel approaches with varying accessibility.
• Physicians face challenges in applying new treatments due to uncertainty and lack of awareness.
• ABCC6 gene variants are central to PXE pathogenesis, impacting pyrophosphate levels and lipid metabolism.

Conclusions:

• A comprehensive understanding of PXE treatment options is crucial for effective patient care.
• Bridging the gap between research advancements and clinical practice is essential for improving outcomes in PXE.
• Continued research and development are vital for advancing therapeutic strategies for Pseudoxanthoma elasticum.